  This report describes a case of osteonecrosis of the jaw developing after a routine dental extraction in a patient being treated with dasatinib , a tyrosine kinase inhibitor , for chronic myelogenous leukemia<disease>. As the role of tyrosine kinase inhibitors in cancer treatment expands , patterns of debilitating complications involving the osseous structures of the oral cavity have begun to emerge , and many long-term side effects of this promising therapy remain unknown. To limit the occurrence of known complications , health care providers and patients must be aware of the potential for serious complications of dasatinib , and appropriate protocols should be in place before administration of this medication.